IGC Pharma Adds Visionary Investigators Network Site to Phase 2 CALMA Trial
IGC Pharma has added the Visionary Investigators Network’s Coconut Grove site in Miami to its Phase 2 CALMA trial, expanding its practice-integrated neurology network and increasing enrollment capacity. The company reports approximately 70% of planned subjects are already enrolled as the randomized, double-blind, placebo-controlled trial advances.
1. Addition of Visionary Investigators Network Site
IGC Pharma has partnered with Visionary Investigators Network (VIN) to add its Coconut Grove, Miami location as a clinical research site in the Phase 2 CALMA trial. VIN’s practice-integrated neurology model embeds research within private practices, offering access to well-characterized Alzheimer’s dementia patients while maintaining continuity of clinical care.
2. Enrollment Progress and Trial Details
The CALMA trial is a randomized, double-blind, placebo-controlled study evaluating IGC-AD1 for agitation in Alzheimer’s disease dementia. With approximately 70% of planned enrollment completed, the addition of VIN is expected to accelerate patient recruitment, sustain engagement and uphold protocol adherence as the trial moves toward full enrollment.